Xeris Biopharma Appoints Ricki Fairley to Board of Directors
30 March 2023 - 7:05AM
Business Wire
Xeris Biopharma Holdings (Nasdaq: XERS), a growth-oriented
biopharmaceutical company committed to improving patient lives by
developing and commercializing innovative products across a range
of therapeutic areas, appointed Ricki Fairley to its Board of
Directors, increasing the size of the Board to nine members, on
March 27, 2023.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230329005369/en/
(Photo: Business Wire)
“On behalf of our Board, we welcome Ricki and her wealth of
insights and experiences, especially her passion for advocating on
behalf of patients,” said Paul R. Edick, Chairman and Chief
Executive Officer of Xeris. “As a seasoned marketer with 35+ years
in brand management and strategic planning, we look forward to
collaborating with Ricki to advance our mission of serving patient
communities.”
Ms. Fairley has over 35 years of marketing experience including
20 years in brand management at Johnson & Johnson, Nabisco,
Reckitt & Colman, and The Coca-Cola Company, and over 15 years
in agency leadership encompassing strategic planning and consulting
for numerous Fortune 500 companies. She currently serves as
co-founder and CEO of TOUCH, The Black Breast Cancer Alliance and
is also co-host for “The Doctor Is In,” a weekly live breast cancer
advocacy web series. In January 2022, Ms. Fairley started the When
We Tri(al) Movement to change the game on Black women participating
in clinical trials to improve outcomes for Black women with breast
cancer that has resulted in thousands of Black women entering
clinical trial research. Ms. Fairley serves on the Board of
Trustees for the Triple Negative Breast Cancer Foundation. She is a
board member for the Center for Healthcare Innovation and serves on
the National Minority Quality Forum Scientific Advisory Board for
Project Moonshot. She is a founding member of the American Cancer
Society’s National Breast Cancer Roundtable Steering Committee.
Prior to founding TOUCH, The Black Breast Cancer Alliance, Ms.
Fairley was the Founder, and served as President and Thought Leader
of DOVE Marketing, a marketing agency with a mission to deliver
iconic thinking, strategic problem solving and creative genius to
clients seeking profitable business results. Ms. Fairley received
the Leadership Award from the Creative Thinking Association of
America and was named a Top 100 Marketer by Black Enterprise
Magazine in February 2011. Ms. Fairley holds a BA from Dartmouth
College and an MBA from Kellogg School of Management at
Northwestern University. She is the President Emeritus of the Black
Alumni of Dartmouth Association and is Board Chair Emeritus of
Kenny Leon’s True Colors Theatre Company.
“I am thrilled to join this board of astute business
strategists. I look forward to bringing my patient advocate voice
to the company’s passionate and committed pursuit of changing
patients’ lives,” says Ricki Fairley.
About Xeris
Xeris (Nasdaq: XERS) is a growth-oriented biopharmaceutical
company committed to improving patients’ lives by developing and
commercializing differentiated and innovative products across a
range of therapies. Xeris has three commercially available
products: Gvoke®, a ready-to-use liquid glucagon for the treatment
of severe hypoglycemia; Keveyis®, a proven therapy for primary
periodic paralysis; and Recorlev® for the treatment of endogenous
Cushing’s syndrome. Xeris has a diverse pipeline of development and
partnered programs using its formulation sciences, XeriSol™ and
XeriJect™, to support long-term product development and commercial
success.
Xeris Biopharma Holdings is headquartered in Chicago, IL. For
more information, visit www.xerispharma.com, or follow us on
Twitter, LinkedIn, or Instagram.
Forward-looking Statements
Any statements in this press release about future expectations,
plans and prospects for Xeris Biopharma Holdings, Inc., including
statements regarding Xeris’ ability to successfully develop and
commercialize differentiated and innovative products and serve
patient communities, and other statements containing the words
“will,” “would,” “continue,” and similar expressions, constitute
forward-looking statements within the meaning of The Private
Securities Litigation Reform Act of 1995. These forward-looking
statements are based on numerous assumptions and assessments made
in light of Xeris’ experience and perception of historical trends,
current conditions, business strategies, operating environment,
future developments, and other factors it believes appropriate. By
their nature, forward-looking statements involve known and unknown
risks and uncertainties because they relate to events and depend on
circumstances that will occur in the future. The various factors
that could cause Xeris’ actual results, performance or
achievements, industry results and developments to differ
materially from those expressed in or implied by such
forward-looking statements, include its limited experience
commercializing pharmaceutical products, it may require additional
capital to sustain its business, whether its products will achieve
and maintain market acceptance, its reliance on third-party
suppliers, including single-source suppliers, the continued impact
of COVID-19 on its business operations, its ability to compete
successfully with existing and potential competitors, and its and
collaborators’ ability to protect its and their intellectual
property and proprietary formulation science. No assurance can be
given that our expectations will be realized and persons reading
this communication are, therefore, cautioned not to place undue
reliance on these forward-looking statements. Additional
information about economic, competitive, governmental,
technological, and other factors that may affect Xeris is set forth
in the "Risk Factors" section of Xeris’ 2022 Annual Report on Form
10-K filed with the U.S. Securities and Exchange Commission, the
contents of which are not incorporated by reference into, nor do
they form a part of, this communication. Forward-looking statements
in this communication are based on information available to us, as
of the date of this communication and, while believed to be
reasonable, actual results may differ materially. Subject to any
obligations under applicable law, we do not undertake any
obligation to update any forward-looking statement whether as a
result of new information, future developments or otherwise, or to
conform any forward-looking statement to actual results, future
events, or to changes in expectations.
The Company intends to use the investor relations portion of its
website as a means of disclosing material non-public information
and for complying with disclosure obligations under Regulation
FD.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230329005369/en/
Investor Contact Allison Wey Senior Vice President, Investor
Relations and Corporate Communications awey@xerispharma.com
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Xeris Biopharma (NASDAQ:XERS)
Historical Stock Chart
From Apr 2023 to Apr 2024